Home
About Us
Company Culture
Milestones
Awards and Honors
Social Responsibility
Talent Development
Hot
Recombinant Protein Product
Research and Innovation
R&D Team
R&D Management
Pipelines
Innovation Achievements
Product Category
Drug Products
Peginterferon Alfa-2b Injection
Pegsomatropin Injection
Pegfilgrastim Injection
Molgramostim
Filgrastim
Oprelvekin
API
Reagents
Growth Factors
Interleukins
Interferons
Enzymes
Others
News
Contact Us
English
简体中文
Home
/
News
News and Events
28 drugs are approved in September 2016 by SFDA
2016
10-26
Read More
SFDA releases 2013 annual report on national adverse drug surveillance
2014
05-29
Read More
World Hepatitis Day 2018: Active prevention, active detection, standardized treatment, comprehensive control of the harmness of hepatitis.
2018
07-27
Read More
National Health and Family Planning Commission: October’s progress and development of two major scientific and technological projects in the field of medicine and health
2020
02-21
Read More
«
1
...
3
4
5
...
9
»
Facebook
Twitter
LinkedIn
Instagram
WELCOME
Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
Fax: +86-592-6889110
international@amoytop.com
Tel: +86-592-6889106
Copyright ©
2023
Amoytop Biotech All Rights Reserved. Support by
Leadong
｜
Sitemap
.
Privacy Policy
Email
international@amoytop.com
reagent@amoytop.com
Tel
+86-592-6889106
cell Phone
+86-18060918257
Leave a Message
Get In Touch
Submit
